Local immune response after intravesical interferon gamma in superficial bladder cancer

British Journal of Urology

Volumn 81, Issue 6, 1998, Pages 875-879

  Stavropoulos, N B ^a,c   Ioachim, E ^a   Pavlidis, N ^c   Pappa, L ^b   Kalomiris, P ^b   Agnantis, N J ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Department of Emergency Medicine   (Greece)

^c G HATZIKOSTA GENERAL HOSPITAL   (Greece)

Author keywords

Interferon gamma; Lymphocytes subsets; MHC II antigens; Superficial bladder cancer

Indexed keywords

CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; RECOMBINANT GAMMA INTERFERON;

AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INTRAVESICAL DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MALE; PRIORITY JOURNAL; SUPERFICIAL CANCER; T LYMPHOCYTE;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; MACROPHAGES; MALE; T-LYMPHOCYTE SUBSETS; URINARY BLADDER NEOPLASMS;

EID: 0031839275     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00646.x     Document Type: Article

References (23)

1. Hiratsuka H, Imamura M, Kasai K et al. Lymphocytes subpopulation and T-cell subsets in human oral cancer tissues. Immunohistologic analysis by monoclonal antibodies. Am I Clin Pathol 1984; 81: 464-70
2. El-Demiry MIM, Smith G, Ritchie AWS et al. Local Immune response after intravesical BCG treatment for carcinoma in situ. BrJUrol 1987; 60: 543-8
3. Prescott S, James K, Bussutil A, Hargreave TB, Chisholm GD, Smyth JF. HLA-DR expression by high grade superficial bladder cancer treated by BCG. Br J Urol 1989; 63: 264-9
4. Ottesen SS, Ahrenkief V, Kieler J. Recombinant human Interferon g exerts an antiproliferative effect and modulates the expression of human leukocyte antigens A, B. C and DR in human urothelial cell lines. Cancer Immunol Immunother 1990; 31: 93-8
5. Hawkyard S, James K, Prescott S et al. The effect of recombinant interferon-gamma on a panel of human bladder cancer cell lines. J Urol 1991: 145: 1078-81
6. Prescot S. James K, Hargreave TB, Chisholm GD, Smyth JF. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 1990: 144: 1248-51
7. Geboers ADH, van Bergen TNLM, Oosterlinck W. Gamma Interferon in the therapeutic and prophylactic treatment of superficial bladder tumours. J Urol 1987; 137: 276A
8. Fellows GJ, Parmar MK, Grigor KM, Hall RR, Heal MR, Wallace DM. Marker tumour response to Evans and Pasteur bacille Calmette-Guerin in multiple recurrent pTa/pTl bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). BrJUrol 1994; 73: 639-44
9. Popert RJ, Goodall J. Coptcoat MJ, Thomson PM. Parmar MK, Masters JR. Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. Br }Urol 1994; 74: 195-9
10. Van der Meijden AP, Hall RR, Macaluso MP, Pawinsky A, Sylvester R, Van Glabbeke M. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer Genitourinary Group (EORTC 30897). Eur Urol 1996; 29: 199-203
11. Trinchieri G, Perusia B. Immune Interferon: a pleiotrophic lymphokine with multiple effects. Immunol Today 1985: 6: 131-6
12. Basham TY. Merigan TC. Recombinant Interferon- increases HLA-DR synthesis and expression. J Immunol 1983: 130: 1492-4
13. Reinherz EL. Norimoto C. Penta AC, Schlossman SF. Regulation of B cell immunoglobulin secretion by functional subsets of T-lymphocytes in man. Eur J Immunol 1980: 10: 570-2
14. Levy PC, Shaw GM, LoBuglio AF. Human monocyte, lymphocyte and granulocyte antibody-dependent cell mediated cytotoxicity toward tumour cells. J Immunol 1979: 123: 594-9
15. 5 Meltzer MS, Benjamin WR. Farrar JJ. Macrophage activation for tumour cytotoxicity: induction of macrophage tumoricidal activity by lymphokines from EL-4, a continuous T cell line. J Immunol 1982: 129: 2802-7
16. Pace JL, Russell SW, Torres BA. Johnson HM, Gray PW. Recombinant mouse y Interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 1983; 130: 2011-3
17. Varesio L, Blasi E, Thurman GB. Talmadge JE. Wiltrout RH. Herberman RB. Potent activation of mouse macrophages by recombinant interferon-y. Cancer Res 1984; 44: 4465-9
18. Benacerraf B, Germain RN. The immune response genes of the major histocompatibility complex. Immunol Rev 1978: 38: 70-119
19. Herzenberg LA, Black SJ, Herzenberg LA. Regulatory circuits and antibody responses. Eur J Immunol 1980; 10: 1-11
20. Hawkyard SJ, Jackson AM. James K, Prescott S, Smyth JF, Chisholm GD. The inhibitory effect of Interferon gamma on the growth of bladder cancer. J Urol 1992: 147: 1399-403
21. Mason DW. The possible role of Class II major histocompatibility complex antigens in self tolerance. Scand J Immunol 1985: 21: 397-400
22. Mac-Moune Lai F. Cheng PNM, Tsao SY. Lai KM. Immunohistological characteristics of the infiltrating lymphoid cells and expression of HLA class I and II antigens in nasopharyngeal carcinoma. Virchows Arch A Pathol Anat 1990: 417: 347-52
23. loachim-Velogianni E, Stavropoulos NE. Kitsiou E, Stefanaki S. Agnantis NJ. HLA-DR antigen expression and lymphocytes subsets in transitional cell carcinoma of the urinary bladder. An immunohistological study on frozen sections. J Pathol 1994: 174: 183-9